Geriatrisch bedeutsame Substanzen

  • Margot Schmitz


Die Alzheimer-Krankheit ist die häufigste geriatrische Krankheit. 5% der über 65-Jährigen leiden daran. Diese Zahl steigt rapide mit dem Lebensalter an, und bei den über 80-Jährigen sind es schon über 10 bis 20%. Allerdings kann die Krankheit schon bei 35-Jährigen beginnen.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. American Psychiatric Association (1995) 148th Annual Meeting. Topic 8: Organic Mental DisordersGoogle Scholar
  2. Ballard CG (2002) Advances in the Treatment of Alzheimer’s Disease: Benefit of Dual Cholinesterase Inhibition. Eur Neurol 47:64–70PubMedCrossRefGoogle Scholar
  3. Bloom FE, Kupfer DJ (eds) (1995) Psychopharmacology. The Fourth Generation in Progress. Geriatric Disorders: 1361–1479; Raven, NYGoogle Scholar
  4. Bullock R, Cameron A (2002) Rivastigmine for the Treatment of Dementia and Visual Hallucinations Associated with Parkinson’s Disease: A Case Series. Current Medical Research and Opinions 18(5):258–264CrossRefGoogle Scholar
  5. Chen P, Ratcliff G, Belle SH et al (2001) Patterns of Cognitive Decline in Presymptomatic Alzheimer Disease. Arch Gen Psychiatry 58:853–860PubMedCrossRefGoogle Scholar
  6. Clark R, Goate A (1993) Molecular genetics of Alzheimer’s disease. Arch Neurol 50:1164–1172PubMedCrossRefGoogle Scholar
  7. Cohen RM, Weingartner HW, Smallberg A, Pickar D, Murphy DL (1982) Effort and cognition in depression. Arch Gen Psychiatry 39:593–597PubMedCrossRefGoogle Scholar
  8. Collis A, Maruff P, Shafiq-Antonacci R et al (2001) Memory decline in healthy older people. Implication for identifying mild cognitive impairment. Neurology 56:1533–1538CrossRefGoogle Scholar
  9. Danyscz W, Parsons CG, Möbius HJ et al (2000) Neuroprotective and Symptomatological Action of Memantine Relevant for Alzheimer’s Disease — Unified Glutamatergic Hypothesis on the Mechanism of Action (1999) Neurotoxicity Research 2:85–97Google Scholar
  10. Davis KL, Thal LJ, Gamzu E et al (1992) Tacrine in patients with Alzheimer’s disease: a double blind placebo controlled multicenter study. N Engl J Med 327:1374–1379CrossRefGoogle Scholar
  11. De Leon MJ (1999) An Atlas of Alzheimer’s Disease. The Encyclopedia of Visual Medicine Series. The Parthenon Publishing Group, New York LondonGoogle Scholar
  12. Erkinjuntti T, Skoog I, Lane R, Andrews C (2002) Rivastigmine in patients with Alzheimer’s disease and concurrent hypertension. IJCP 56(10):791–796PubMedGoogle Scholar
  13. Erkinjuntti T, Kurz A, Gauthier S et al (2002) Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 359:1283–1290PubMedCrossRefGoogle Scholar
  14. Feldman H, Gauthie S, Hecker J et al (2001) A 24 week, randomized double blind study of donepezil in moderate to severe Alzheimer’ disease. Neurology 57:613–620PubMedCrossRefGoogle Scholar
  15. Freeman TW, Clothier JL, Pazzaglia P et al (1992) A Double-blind Comparison of Valproate and Lithium in the Treatment of Acute Mania. Am J Psychiatry 149:108–111PubMedGoogle Scholar
  16. Herrmann N (2001) Recommendations for the management of the behavioral and psychological symptoms of dementia. Can J Neurol Sci 28(suppl l):96–107Google Scholar
  17. Hitzenberger G, Rameis H, Manigley C (1998) Pharmacological Properties of Piracetam. CNS Drugs 9(suppl l):19–27CrossRefGoogle Scholar
  18. Jackson G (ed) (2002) Cholinesterase inhibitors: relating pharmacological properties to clinical profiles. Int J Clin Practice, Suppl 127Google Scholar
  19. MacLean LE, Collins CC, Byrne EJ (2001) Dementia with Lewy bodies treated with rivastigmine. Effects on cognition, neuropsychiatric symptoms and sleep. Int Psychogeriatr 13:277–288PubMedCrossRefGoogle Scholar
  20. Mega MS (2002) Differential Diagnosis of Dementia: Clinical Examination and Laboratory Assessment.
  21. Mohs RC (1991) Assessment of cognitive symptoms in clinical studies of antidementia drugs (Homma A. trans). Jpn J Geriatr Psychiatry 2:1195–1201Google Scholar
  22. Morris JC, Storandt M, Miller P et al (2001) Mild cognitive impairment represents early stage Alzheimer’s disease. Arch Neurol 58:397–405PubMedCrossRefGoogle Scholar
  23. Morris JC (2002) Is Mild Cognitive Impairment Simply Incipient Alzheimer’s Disease? 54th Annual Meeting Denver, April 13-20, 2002 2BS.005 Education ProgramGoogle Scholar
  24. Nigel H, Greig NH et al (2001) A New Therapeutic Target in Alzheimer’s Disease Treatment: Attention to Butyrylcholinesterase. Current Medical Research and Opinion 17, no 3Google Scholar
  25. Prasher VP, Huxley A, Haque MS (2002) A 24 week, double blind placebo controlled trial of donepezil in patients with Down syndrome and Alzheimer’s disease. Pilot study. Int J Geriatr Psychiatry 17:270–278PubMedCrossRefGoogle Scholar
  26. Pierpaoli W, Regelson W, Fabris N (eds) (1994) The Aging Clock. Ann NY Acad Sci 719Google Scholar
  27. Rapoport SI, Grady CL (1993) Parametric in vivo brain imaging during activation to examine pathological mechanisms of functional failure in Alzheimer’s disease. J Neurosci 70:39–56Google Scholar
  28. Reisberg B, Finkel S, Overall J et al (2001) The Alzheimer’s Disease Activities of Daily Living International Scale (ADL-IS). Int Psychogeriatr 13:163–181PubMedCrossRefGoogle Scholar
  29. Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL (1990) Evidence that β-amyloid protein in Alzheimer’s disease is not derived by normal processing. Science 248:492–495PubMedCrossRefGoogle Scholar
  30. Tariot P (2001) Current status and new developments with galantamine in the treatment of Alzheimer’s disease. Expert Opin Pharmacother 2(12):2027–2049PubMedCrossRefGoogle Scholar
  31. Venneri A, Shanks MF, Staff RT et al (2002) Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s disease: Cognitive Neuroscience and Neuropsychology 13(l):83–87Google Scholar
  32. Winblad B, Poritis N (1999) Memantine bei schwerer Demenz. Ergebnisse der M-BEST-Studie. Int J Geriat Psychiatry 14:135–146CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Margot Schmitz
    • 1
    • 2
  1. 1.WienAustria
  2. 2.WienAustria

Personalised recommendations